miltefosine
Mechanisms of ResistanceChemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma bruceiThe arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite ...
PharmacologySystematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through ImmunomodulationHost immune responses are pivotal for the successful treatment of the leishmaniases, a spectrum of infections caused by Leishmania parasites. Previous studies speculated that augmenting cytokines associated with a type 1 T-helper cell (Th1) response is necessary to combat severe forms of leishmaniasis, and it has been hypothesized that the antileishmanial drug miltefosine is capable of immunomodulation and induction of Th1...
Experimental TherapeuticsEfficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed MiceWe evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. Azithromycin was the only treatment able to reduce mortality.
Experimental TherapeuticsMiltefosine Reduces the Cytolytic Activity and Virulence of Acinetobacter baumannii...Stagnation in antimicrobial development has led to a serious threat to public health because some Acinetobacter baumannii infections have become untreatable. New therapeutics with alternative mechanisms of action to combat A. baumannii are therefore necessary to treat these infections.
Mechanisms of ResistanceLipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host MacrophagesThe oral drug miltefosine (MIL) was introduced in the Indian subcontinent in the year 2002 for the treatment of visceral leishmaniasis (VL). However, recent reports on its declining efficacy and increasing relapse rates pose a serious concern.
- Mechanisms of Action: Physiological EffectsMiltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts
Cryptococcus spp. are common opportunistic fungal pathogens, particularly in HIV patients.
- Mechanisms of Action: Physiological EffectsComplex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine
- Mechanisms of Action: Physiological EffectsSynthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine
- Mechanisms of Action: Physiological EffectsFunctional Involvement of Leishmania donovani Tryparedoxin Peroxidases during Infection and Drug Treatment